As of September 30, the company had $30.8M in cash, cash equivalents and short-term investments. “This has been yet another exciting quarter for Regulus as our Phase 1b MAD study of RGLS8429 for the treatment of ADPKD continues to advance. In September, we announced positive topline data for the first cohort. We have since completed enrollment in our second cohort, and, in addition, we dosed the first patient in the third cohort in early November,” said CEO Jay Hagan. “We enjoyed having the opportunity to describe the unique mechanism and benefits of RGLS8429 during our investor event that took place on September 6th. I want to extend another big thank you to Drs. Peter Harris, Tim Kline, Vishal Patel, and Alan Yu for their participation and insight. We remain focused on our goal of bringing life-changing therapeutics to patients with orphan kidney diseases, and we are looking forward to continuing to share study and data updates as they become available, including cohort two topline data in Q1 of 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RGLS:
- Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
- Regulus Therapeutics Inc (RGLS) Q3 Earnings Cheat Sheet
- Regulus: First patient dosed in third cohort of Phase 1b MAD study of RGSL8429
- Regulus advances to cohort 3 of Phase 1b trial of ADPKD trial
- Regulus price target raised to $12 from $9 at Canaccord